Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry

Brunangelo Falini and David Y. Mason

Acquired chromosomal anomalies (most commonly translocations) in lymphoma and leukemia usually result in either activation of a quiescent gene (by means of immunoglobulin or T-cell–receptor promoters) and expression of an intact protein product, or creation of a fusion gene encoding a chimeric protein. This review summarizes current immunocytochemical studies of these 2 categories of oncogenic protein, with emphasis on the clinical relevance of their detection in diagnostic samples. Among the quiescent genes activated by rearrangement, expression of cyclin D1 (due to rearrangement of the CCND1 [BCL-1] gene) is a near-specific marker of t(11;14) in mantle cell lymphoma; BCL-2 expression distinguishes follicular lymphoma cells from their nonneoplastic counterparts in reactive germinal centers and appears to be an independent prognostic marker in diffuse large cell lymphoma; and TAL-1 (SCL) expression identifies T-cell acute lymphoblastic neoplasms in which this gene is activated. The protein products of other genes activated by chromosomal rearrangement have a role as markers of either lineage (eg, PAX-5 [B-cell–specific activator protein] for B cells, including B-lymphoblastic neoplasms), or maturation stage (eg, BCL-6 for germinal-center and activated B cells and MUM-1/IRF4 for plasma cells). Currently, no hybrid protein encoded by fusion genes is reliably detectable by antibodies recognizing unique junctional epitopes (ie, epitopes absent from the wild-type constituent proteins). Nevertheless, staining for promyelocytic leukemia (PML) protein will detect acute PML with t(15;17) because the microspeckled nuclear labeling pattern for PML-RARα is highly distinctive. Similarly, antibodies to the anaplastic lymphoma kinase (ALK) tyrosine kinase are valuable (because wild-type ALK is not found in normal lymphoid tissue) in detecting neoplasms (CD30-positive large T-cell lymphomas) with t(2;5) or its variants. Thus, immunocytochemical detection of the products of many rearranged genes in lymphoma and leukemia can be clinically informative and provide information on cellular and subcellular protein expression that cannot be inferred from studies based on messenger RNA. (Blood. 2002;99:409-426)

Introduction

Translocations, deletions, and other nonrandom chromosomal abnormalities1,2 play a central role in the pathogenesis of many human hematologic malignant diseases. A growing number of studies are revealing the ways in which these chromosomal alterations affect specific genes, such as those encoding nuclear transcription factors. However, any gene implicated in the neoplastic process can act only through the protein it encodes. Many of the consequences of chromosomal changes with respect to abnormal protein expression have been inferred indirectly by analysis of messenger RNA (mRNA) transcription, but it is clear that protein and mRNA levels do not always correlate. For example, germinal-center B cells appear to contain BCL-2 message but little protein,3,4 and the same is true for TAL-1 in erythroid cells.5 Many examples of the opposite combination (high protein and little or no message) also exist, such as BCL-2 in mature lymphocytes6,7 and elastase in mature myeloid cells.8 Antibody-based detection of the protein is therefore required, but this frequently cannot be done because of a lack of suitable reagents. Consequently, we are often ignorant not only about patterns of expression of oncogenic proteins in hematologic neoplasms but also about possible abnormalities in the distribution and subcellular localization of these proteins.

Most of the currently recognized genetic alterations in human leukemias and lymphomas result in either activation of a quiescent gene or creation of a hybrid gene encoding a chimeric protein. Table 1 summarizes the genetic abnormalities that have been studied using antibodies specific for the protein products of genes involved in such rearrangements. We here review the immunocytochemical studies that have been done with these antibodies and assess, for each protein, whether abnormalities demonstrable by immunocytochemistry are of clinical value in determining diagnosis or predicting prognosis. Immunocytochemical findings that are of value are discussed below, whereas those for which no clear clinical applications have been observed are described briefly in Table 2.

Table 1 summarizes the genetic abnormalities that have been identified by immunofluorescence and/or immunohistochemistry. The abnormalities that have been associated with chromosomal translocations are listed in the left column of the table; the right column indicates the neoplasms in which they are found. The table is divided into 3 major sections: 1) genetic changes affecting the monocytic lineage (eg, PML-RARα, APL with t(15;17)), 2) abnormalities specifically affecting T-cell lymphomas (eg, ALK tyrosine kinase, TdT), and 3) abnormalities of B-cell lymphomas (eg, BCL-2, cyclin D1).

Table 2 summarizes the genetic abnormalities that have been associated with acquired chromosomal anomalies and that have been studied using antibodies specific for the protein products of genes involved in such rearrangements. We here review the immunocytochemical studies that have been done with these antibodies and assess, for each protein, whether abnormalities demonstrable by immunocytochemistry are of clinical value in determining diagnosis or predicting prognosis. Immunocytochemical findings that are of value are discussed below, whereas those for which no clear clinical applications have been observed are described briefly in Table 2.

The authors contributed equally to this work.

Reprints: Brunangelo Falini, Istituto di Ematologia, Policlinico, Monteluce, 06100 Perugia, Italy.
the transition from G1 to S. 16
protein may promote neoplastic cell proliferation by perpetuating normal lymphohemopoietic tissues 14,15; thus, expression of the mas express cyclin D1, 22-25 although the staining intensity and the percentage of positive cells differ from case to case. 15 Immunostain-

**Table 1. Gene products involved in leukemia and lymphoma**

<table>
<thead>
<tr>
<th>Genetic anomaly</th>
<th>Genes</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(11;14)(q23;q32)</td>
<td>BCL-1 and IgH</td>
<td>Mantle cell lymphoma</td>
</tr>
<tr>
<td>t(14;18)(q32;q21)</td>
<td>BCL-2 and IgH</td>
<td>Follicular lymphoma</td>
</tr>
<tr>
<td>Miscellaneous anomalies involving 3q27</td>
<td>BCL-6</td>
<td>Diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>t(14;14)(p22;p21) and del(14)(q11)</td>
<td>TAL-1 and TCF3 or SIL</td>
<td>T-cell acute lymphoblastic leukemia</td>
</tr>
<tr>
<td>t(2;8)(p24;p24) and variants</td>
<td>c-MYC and IgH or IgL</td>
<td>Burkitt lymphoma</td>
</tr>
<tr>
<td>t(8;14)(q22;q32)</td>
<td>MUM1/IRF4 and IgH</td>
<td>Myeloma</td>
</tr>
<tr>
<td>t(8;14)(p13;q22)</td>
<td>PAX-5 (BSAP)</td>
<td>Immunocytoa</td>
</tr>
</tbody>
</table>

**Table 2. Oncogene products detectable immunocytochemically in neoplastic hemopoietic cells for which no clinical applications have been defined**

<table>
<thead>
<tr>
<th>Oncogene</th>
<th>Genetic abnormality</th>
<th>Protein product(s)</th>
<th>Localization in normal tissue</th>
<th>Studies of neoplastic hemopoietic cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>c-MYC</td>
<td>Fuses to Ig genes in t(8;14), t(2;8), and t(8;22)</td>
<td>MYC protein dimerizes with MAX and binds to DNA</td>
<td>Widely distributed[^{233-235}]</td>
<td>Widely expressed in hemopoietic neoplasms; correlation with tumor grade in lymphoma claimed[^{233,235}] but not confirmed</td>
</tr>
<tr>
<td>BCR and ABL</td>
<td>t(9;22) creates a hybrid gene</td>
<td>ABL: nuclear kinase; BCR: DNA-binding protein with kinase domain</td>
<td>ABL: present in many cell types, ? nuclear, ? cytoplasmic[^{247-250}]; BCR: in cytoplasm of many cells[^{250-251}]</td>
<td>Several antibody-based studies of BCR-ABL[^{254,250,250-252}] but no diagnostic applications</td>
</tr>
<tr>
<td>MLL (HRX)</td>
<td>A variety of translocations fuse MLL to other genes</td>
<td>DNA-binding protein, homologous to trithorax in Drosophila</td>
<td>Ubiquitous nuclear expression with tendency to localize to small dotlike structures[^{252}]</td>
<td>Chimeric proteins do not differ in immunocytochemical staining from wild-type MLL (HRX)[^{253}]; Reported that antibodies specific for E2A-PBX junction can be used in diagnosis of leukemia,[^{258,253}] but no subsequent studies</td>
</tr>
<tr>
<td>E2A</td>
<td>E2A fuses to PBX and HLF in t(1;19) and t(17;19), respectively</td>
<td>Transcription factors</td>
<td>Limited data</td>
<td></td>
</tr>
</tbody>
</table>

**Cyclin D1 in lymphoid neoplasia.** Most mantle cell lymphomas express cyclin D1,22-25 although the staining intensity and the percentage of positive cells differ from case to case. 15 Immunostaining is usually seen in a diffuse pattern in cell nuclei,15,24 but cytoplasmic positivity is also occasionally observed.17 The blastoid form of mantle cell lymphoma,26 characterized by frequent rearrangement of the CCND1 (BCL-1) gene, a high mitotic index, and a tendency to localize to small dotlike structures292, is a near-specific marker is clearly valuable, particularly when a poor biopsy or an unusual growth pattern hinders recognition of the disease. Because mantle cell lymphoma has a range of morphologic features (from a small cell tumor to a blastoid proliferation11,296) and growth patterns (diffuse, nodular, or mantle zone23,37), a near-specific marker is clearly valuable, particularly because survival in this disease is significantly worse than that in other small cell B-cell lymphomas.11,37,38 In addition, cyclin D1 immunostaining may distinguish multiple lymphomatous polyposis from other indolent intestinal lymphomas, and the blastoid variant of mantle cell lymphoma (BCL-1 positive) from B-lymphoblastic lymphoma/leukemia (BCL-1 negative).25 Cyclin D1
immunostaining has also been used to identify cases of mantle cell lymphoma in a leukemic phase (a poor prognostic condition) and to differentiate them from other atypical chronic lymphoproliferative disorders.39,40

The BCL-2 gene and its protein product

**BCL-2 gene.** The (14;18) chromosomal translocation in follicular lymphoma involves the BCL-2 gene at the chromosome 18 breakpoint, which encodes a 26-kd protein with limited homology to an Epstein-Barr viral protein (BHRF-1).41 Because breakpoints occur in the 3' untranslated region, full-length protein is expressed after juxtaposition of the gene to the immunoglobulin heavy-chain promoter.41 Extensive studies have documented the role of BCL-2 in blocking apoptosis in many cell types and in response to a variety of stimuli.41 Many cellular and viral homologues have also been identified.

**Antibodies to BCL-2.** Mouse and hamster monoclonal antibodies (mAbs) to BCL-2 protein have been described (Table 3).42 One of these, the mouse monoclonal reagent designated BCL-2/124,7 is used in many of the immunocytochemical studies discussed below.

**BCL-2 in normal tissues.** BCL-2 is associated with mitochondria and cell membranes43 and is widely distributed in both hemopoietic and nonhemopoietic cells.42 However, BCL-2 is absent from B-lymphoid cells in the germinal centers of B-cell follicles and from cortical thymocytes,44,46 and it ceases to be detectable when cells are transformed (eg, by miotogens).47

**BCL-2 in hematologic neoplasia.** BCL-2 protein is expressed in most cases of follicular lymphoma,47 both in the majority with t(14;18) and in many without it.48,49 However, a few cases lack both protein expression and rearrangement.50 BCL-2 protein is also expressed in many lymphoid and myeloid neoplasms,5,51-56 although it is usually absent or expressed at low levels in Burkitt lymphoma53,54 and anaplastic lymphoma kinase (ALK)–positive anaplastic large cell lymphoma (ALCL).58,59 possibly because of the high rate of cell proliferation.60 BCL-2 protein is also often absent or present at low levels in large B-cell tumors at

---

**Table 3. Murine monoclonal antibodies for detection of proteins encoded by genes involved in hematologic neoplasia**

<table>
<thead>
<tr>
<th>Antibody*</th>
<th>Fixation resistance of epitope</th>
<th>Immunocytochemical staining pattern on lymphoid and hemopoietic cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCL-1/Cyclin D1</td>
<td>17,18,234</td>
<td>Nuclear Negative Mantle cell lymphoma†</td>
</tr>
<tr>
<td>5D4, DCS-6</td>
<td>Yes</td>
<td>Nuclear Broad (but germinal-center B cells negative) Broad (including follicular lymphoma)</td>
</tr>
<tr>
<td>BCL-2*</td>
<td>Cytoplasmic</td>
<td>Erythroid and megakaryocytic cells T-cell acute lymphoblastic neoplasms (minority)</td>
</tr>
<tr>
<td>Bcl-2/100, Bcl-2/124</td>
<td>Yes</td>
<td>Nuclear Broad (spectacle) T-cell acute lymphoblastic neoplasms (minority)</td>
</tr>
<tr>
<td>BCL-6</td>
<td>106</td>
<td>Nuclear B-cell precursors and mature B cells B-cell neoplasms (including lymphoblastic)</td>
</tr>
<tr>
<td>PML</td>
<td>154,155</td>
<td>Nuclear Erythroid and megakaryocytic cells T-cell acute lymphoblastic neoplasms (minority)</td>
</tr>
<tr>
<td>PG-M3, §5E10</td>
<td>Yes</td>
<td>Nuclear and/or cytoplasmic Nuclear (speckled) Negative ALCL</td>
</tr>
<tr>
<td>ALK1, ALKc</td>
<td>Yes</td>
<td>Nuclear Erythroid and megakaryocytic cells T-cell acute lymphoblastic neoplasms (minority)</td>
</tr>
<tr>
<td>NPM</td>
<td>207,223</td>
<td>Nuclear Erythroid and megakaryocytic cells T-cell acute lymphoblastic neoplasms (minority)</td>
</tr>
<tr>
<td>37/5.1, NPMc#</td>
<td>Yes</td>
<td>Nuclear B-cell precursors and mature B cells B-cell neoplasms (including lymphoblastic)</td>
</tr>
<tr>
<td>NA24, NPMa**</td>
<td>Yes</td>
<td>Nuclear B-cell precursors and mature B cells B-cell neoplasms (including lymphoblastic)</td>
</tr>
</tbody>
</table>

MM indicates multiple myeloma; HD, Hodgkin disease; ALCL, anaplastic large cell lymphoma; and APL, acute promyelocytic leukemia.

*Monoclonal antibodies showing reactivities similar to those of the monoclonal antibodies discussed in this article have been reported for cyclin D1,235 IRF4/ICSAT (Santa Cruz); PAX-5,131 HRX,296 and ALK.220,225,226

†Optimal results are obtained after microwave heating and overnight incubation with the primary antibody.

‡Only antibody P6-B6p reacts in paraffin sections (dependent on microwave heating in 1 mM EDTA [pH 8.0]).

§Antibody 2TL73 has been used to stain paraffin sections, but results are not optimal (excessive background labeling).

¶Monoclonal antibody PG-M3154 is preferred to antibody 5E10,155,178 whose epitope (between amino acids 448 and 466) is lost in some forms of PML-RARα (eg, bcR3).156

Given the known frequency of involvement of breakpoint region 3 in APL,149 antibody 5E10 is likely to detect no more than 60% of APL cases.

††Directed against the carboxy-terminal of NPM (not present in the NPM-ALK fusion protein).

**Both directed against the amino-terminal of NPM (present in the NPM-ALK fusion protein).
extranodal sites, including the gastrointestinal tract. In contrast, lymph node–based B-cell neoplasms are commonly positive for BCL-2. Furthermore, although low-grade mucosa-associated lymphoid tissue (MALT) lymphomas of the gastrointestinal tract are BCL-2 positive, they often contain areas of larger cells that lack BCL-2 (Figure 2A), probably representing early transformation to large cell neoplasms. This may be relevant to observations that large B-cell neoplasms arising from MALT are BCL-2 negative and that proliferative markers in nodal lymphomas are inversely related to expression of BCL-2.

In follicular lymphomas, BCL-2 expression may also be heterogeneous, and the BCL-2–negative cells tend to be centroblasts (large noncleaved cells) rather than centrocytes (Figure 2B). As a result, cases at the aggressive end of the morphologic spectrum may appear to be BCL-2 negative when, in reality, few cells express the protein. This “pseudonegative” pattern is accentuated by the tendency of centrocytes to migrate away from neoplastic follicles so that large nodules of BCL-2–negative centroblasts are observed, with intervening smaller neoplastic cells that can be mistaken for normal cells (Figure 2B). It is possible that the BCL-2–negative large cell component is more sensitive to chemotherapy than is the small cell component, which may therefore persist and account for the indolent progression of the disease.

BCL-2 protein is found in Reed-Sternberg cells in one third to three fourths of all biopsy specimens from patients with Hodgkin disease (HD), including a few who have also had follicular lymphoma, but this presumably reflects its ubiquitous presence in lymphoid cells. However, the neoplastic cells of lymphocyte predominance HD (lymphocytic and histiocytic [L&H] or popcorn cells) tend to be BCL-2 negative, thereby illustrating the distinct nature of this HD subtype.

Figure 2. BCL-2 immunostaining of neoplastic lymphoid tissue. (A) In a low-grade MALT lymphoma, BCL-2 is expressed by the diffuse neoplastic infiltrate lying beneath the intestinal mucosa (Muc). BCL-2 is absent from reactive germinal centers (asterisks) in the tumor and from areas of high-grade transformation. The high-power view (bottom) shows the border between a low-grade area and a high-grade area. The arrows indicate large BCL-2–negative neoplastic cells. Original magnification top, ×200; bottom, ×800. (B) A pseudonegative follicular lymphoma in which the cells in a neoplastic follicle (Foll) lack BCL-2. However, a higher-power examination of the boxed area (center and bottom) shows that many of the BCL-2–positive small interfollicular cells (arrows) are neoplastic centrocytes (small cleaved cells). (Alkaline phosphatase–antialkaline phosphatase [APAAP] technique in paraffin sections; reproduced with permission from American Journal of Pathology.) Original magnification top, ×250; center, ×400; bottom, ×800.

Figure 3. BCL-6 immunostaining of normal and neoplastic lymphoid cells. (A) BCL-6 expression in germinal centers in a lymph node showing follicular hyperplasia. (B) Diffuse large B-cell lymphoma. At left is a section stained with hematoxylin and eosin, and at right is a sample with BCL-6 immunostaining showing strong nuclear expression. (C) A trapped germinal center in a mantle lymphoma is BCL-2 negative (left) and BCL-6 positive (right). (D) BCL-6 expression by a popcorn/L&H cell (arrow) in nodular lymphocyte predominance HD (APAAP technique in paraffin sections; reproduced with permission from American Journal of Pathology.) Original magnification A, ×100; B left, ×800; B right, ×800; C left, ×200; C right, ×200; D, ×800.
Clinical applications of BCL-2 immunostaining. Although the ubiquitous distribution of BCL-2 protein limits its value for diagnosis, it is widely used for distinguishing reactive lymphoid follicles, which are BCL-2 negative, from neoplastic follicles and proliferation centers (found in chronic lymphocytic leukemia67-73), both of which are usually BCL-2 positive. In MALT lymphoma, for example, the reactive lymphoid follicles characteristically associated with this tumor (which may be confused with follicular lymphoma) are clearly negative (Figure 2A),64 at least until they have undergone follicular colonization by neoplastic cells.74 A similar phenomenon has been observed in mantle cell lymphomas that localize around germinal centers (Figure 3C).72

BCL-2 may also be of value as a marker for identifying infiltration by follicular lymphoma cells in bone marrow trephine biopsy specimens.75,76 Aggregates of normal or reactive lymphoid cells often stain only weakly (although T cells label more strongly than B cells) and have nondescript nuclear morphologic features. In contrast, follicular lymphoma cells show strong cytoplasmic BCL-2 labeling, which tends to emphasize their characteristic cleft nuclear morphologic features (Figure 2B), and this is often a valuable adjunct to the classical criterion of a paratrabecular infiltration pattern. It is also possible that cases of “Burkitt-like” lymphoma can be distinguished from epidemic/sporadic Burkitt lymphoma by the expression of BCL-2 protein,57 as can cases of lymphoblastic lymphoma/leukemia,77 although further studies of this issue are needed.

It has been suggested that the presence of high levels of BCL-2 protein promotes survival of neoplastic cells78 or confers drug resistance79 (or both) and thus is a marker of a poor prognosis. Many clinical studies have sought evidence of such a correlation, and an association between higher cellular BCL-2 levels and poorer disease-free survival at periods up to 10 years was found in several studies of diffuse large cell lymphoma (DLCL).80-86 There is also some evidence for a prognostic influence of BCL-2 levels in acute myeloid leukemia.87-91 However, for other hematologic malignant diseases (HD),92 follicular lymphoma,93,94 chronic lymphocytic leukemia,95,96 and acute lymphoblastic leukemia [ALL],97-99, the data are limited or equivocal.

Diffuse lymphomas therefore represent the most promising area for future studies of BCL-2 expression and offer the longer-term prospect of strategies for specifically inhibiting BCL-2.86 However, few if any oncologists currently take BCL-2 levels into account when treating individual patients, and this variable has not been used in any controlled trials to assign patients with lymphoma to more aggressive treatment protocols.

The BCL-6 gene and its protein product

BCL-6 gene. Studies in knockout mice found that BCL-6 protein is required for germinal-center formation, antibody-affinity maturation, and T-helper-2–mediated responses.100 BCL-6 appears to inhibit differentiation of germinal-center B cells toward plasma cells by binding to signal transducers and activators of transcription 3, thereby preventing the expression of Blimp-1 (a major regulator of plasma cell development).101

Chromosomal translocations involving the 5′ noncoding domain of the BCL-6 gene at band 3q27 are observed in about 40% of diffuse large B-cell lymphomas and 10% to 15% of follicular lymphomas, juxtaposing the gene to promoters from a variety of partner chromosomes (most commonly in immunoglobulin chain loci). Mutations of the regulatory part of the BCL-6 gene are virtually absent in ALL and mantle cell lymphoma, but they occur frequently in germinal-center and postgerminal-center lymphomas, including follicular lymphomas, DLCLs, and Burkitt lymphomas.104 However, mutations of the BCL-6 gene have also been found in normal germinal-center B cells,105 and it is not clear what role they play in lymphomagenesis.

Antibodies to BCL-6. Two mAbs (PG-B6p and PG-B6a) have been raised against a recombinant BCL-6 protein (Table 3). PG-B6p, which recognizes a formalin-resistant amino-terminal epitope, labels routinely processed biopsy specimens.106

BCL-6 in normal tissues. In lymphoid tissues, BCL-6 protein is expressed in germinal-center B cells in secondary follicles (Table 3 and Figure 3A)106-111 in both the dark (centroblast-rich) and light (centrocyte-rich) zones.106-110 It is also detectable in a few CD4-positive T cells, both in the germinal centers and in interfollicular areas,107,108 and in perifollicular CD30+ lymphoid cells.107 In addition, BCL-6 protein is expressed in thymocytes, mainly in the cortex.112 Outside the lymphohemopoietic system, expression of BCL-6 has been observed in squamous epithelia,106,113 In all positive cells, BCL-6 protein localizes to the nucleus in a diffuse or microgranular pattern.106-108,110

BCL-6 in lymphoid neoplasia. Strong nuclear expression of BCL-6 occurs frequently in follicular lymphomas, paralleling its presence in germinal-center cells, their normal counterpart. BCL-6 expression is also found in most Burkitt lymphomas and diffuse large B-cell lymphomas (Figure 3B), regardless of whether the gene is rearranged.106-108,110,114 In lymphomas associated with human immunodeficiency virus, expression of BCL-6 and expression of the Epstein-Barr viral protein LMP1 appear to be mutually exclusive.115

Neoplasms of B cells unrelated to germinal centers (eg, B-cell precursor malignant diseases, B-CLL, mantle cell and marginal zone lymphomas, and hairy cell leukemia) consistently lack BCL-6 protein (Figure 3C),106 in keeping with its absence from the putative normal counterparts of these neoplasms.11,116 Among T-cell lymphomas, BCL-6 expression has been detected in about 50% of ALCLs117 and T-cell lymphoblastic lymphomas.112 Reed-Sternberg cells in classic HD are usually BCL-6 negative, but the tumor cells (L&H cells) in lymphocyte predominance HD are strongly positive (Figure 3D),118 in keeping with their probable germinal-center origin.69,119

Clinical applications of BCL-6 immunostaining. BCL-6 is a valuable marker of B cells of germinal-center origin.106,110,120 BCL-6 immunostaining, used in conjunction with BCL-2, may be useful in characterizing nodular lymphoid regions, since these can represent neoplastic germinal centers (indicative of follicular lymphoma), trapped residual germinal centers (eg, in MALT and mantle cell lymphomas; Figure 3C), or proliferation centers (in B-CLL).121 Labeling for BCL-6 may also help in the recognition of lymphocyte predominance HD (Figure 3D).118,122

The MUM1/IRF4 gene and its protein product

MUM1/IRF4 gene. The 14q+ cytogenetic anomaly in multiple myeloma represents a cryptic t(6;14)(q25;p32) that juxtaposes the immunoglobulin heavy-chain locus to a gene known as MUM1 or IRF4.123 The MUM1/IRF4 gene encodes a transcription factor thought to play a key role in lymphoid development, since IRF4-deficient mice have a block in peripheral B-cell maturation (absence of germinal centers and plasma cells) associated with a lack of cytotoxic T-cell responses.124

Antibody to MUM1/IRF4. A recently generated mAb (MUM1p)125 against human MUM1/IRF4 protein is suitable for
immunostaining routinely prepared paraffin sections and for Western blotting, in which it detects a 50-kd band of expected molecular weight.

**MUM1/IRF4 in normal tissues.** In normal lymphoid tissue (Table 3), MUM1/IRF4 protein is detected mainly in plasma cells and in a small number of germinal-center B cells, which are usually BCL-6 negative and nonproliferating (Ki67 negative) and found mainly in the light zone of the germinal center. In addition, MUM1/IRF4 is expressed in a small percentage of T cells and in most perifollicular CD30-positive cells, in keeping with its expression by peripheral blood T cells after stimulation with phytohemagglutinin. In all positive cells, MUM1/IRF4 protein expression is primarily nuclear and shows a microgranular and diffuse pattern, with sparing of nucleoli.

**MUM1/IRF4 in lymphoid neoplasia.** In accordance with its expression at late stages of B-cell differentiation and after T-cell activation, MUM1/IRF4 protein is strongly expressed in lymphoplasmacytic lymphoma/immunocytoma, about 75% of diffuse large B-cell lymphomas, primary effusion lymphomas, HD, multiple myeloma, and ALCL. In all positive cells, MUM1/IRF4 protein expression is primarily nuclear and shows a microgranular and diffuse pattern, with sparing of nucleoli.

**Clinical applications of MUM1/IRF4 immunostaining.** Because of the restriction of MUM1/IRF4 to late-stage B cells, it is potentially valuable (used in combination with other plasma cell markers, such as CD138) for recognizing myelomas (Figure 4A). Furthermore, its consistent expression in neoplastic cells in HD (Figure 4B) can be of diagnostic help when the staining highlights Reed-Sternberg and Hodgkin cells in a tissue biopsy specimen (eg, of bone marrow).

**The PAX-5 gene and its protein product**

**PAX-5 gene.** The Pax-5 gene (a member of the paired-box Pax gene family) encodes the transcription factor B-cell–specific activator protein (BSAP), which plays a key role in B-lymphoid development and is also involved in the embryonic development of the central nervous system and testis. In the t(8;14)(p13;q32), which is characteristic of small lymphocytic lymphoma with plasmacytoid differentiation (immunocytoma), the Pax-5 gene (on 9p13) is juxtaposed to the immunoglobulin heavy-chain gene (on 14q32).

**Antibodies to PAX-5.** A polyclonal antibody to PAX-5 has been described and a mAb is available commercially (Transduction Laboratories, Lexington, KY; Table 3). Both detect PAX-5 protein in paraffin-embedded samples.

**Expression of PAX-5 in normal tissues.** In tissue sections, PAX-5 protein can be stained in B-cell follicles but not plasma cells. Unlike B-cell–associated transcription factors such as BCL-6 and MUM1, which are also expressed in activated T cells, PAX-5 appears to be B-cell specific (Table 3). Experimental studies have shown that PAX-5 protein is expressed in B-lymphoid precursors, but no data on direct immunostaining in human bone marrow have been reported.

**Expression of PAX-5 in lymphohemopoietic neoplasms.** PAX-5 has been found in many B-cell lymphomas (with the strongest expression in follicular, mantle cell, and DLCLs) but not in T-cell neoplasms.

**Clinical applications of PAX-5 immunostaining.** PAX-5 may prove to be a valuable diagnostic marker in paraffin-embedded biopsy specimens of B-lymphoblastic neoplasms because it is expressed strongly in such samples and is negative in T-cell lymphoblastic proliferations (Figure 5A; B.F., unpublished data, 2001). HD sometimes mimics ALCL, and PAX-5 may be useful in such cases because Reed-Sternberg cells are usually positive (Figure 5B), whereas ALCLs (both ALK positive and ALK negative) are consistently negative for PAX-5.

**The TAL-1 gene and its protein product**

**TAL-1 gene.** The Tal-1 gene (also known as Scl or Tcl-5) at 1p32 encodes a 42-kd nuclear protein that is essential for mammalian hematopoiesis and normal yolk sac angiogenesis.
Structural alterations in the TAL-1 gene represent the most frequent molecular lesions in T-cell ALL (T-ALL). In up to 25% of childhood cases, a submicroscopical 90–kilobase-pair deletion on the 5' side of the gene brings it under the influence of promoters for the SIL gene. Much less commonly, the gene is rearranged by a chromosome translocation; this is usually t(1;14)(p32;q11), which associates the gene with the TCRb locus.

**Antibodies to TAL-1.** Several mAbs suitable for immunocytochemical detection of TAL-1 have been described (Table 3). TAL-1 in normal tissues. Studies of TAL-1 protein or TAL-1 mRNA found that the gene is expressed in some, but not all, hemopoietic lineages (notably, erythroid precursors, megakaryocytes, and mast cells; Figure 6A). But it is not detectable in even the most immature T cells (thymocytes and CD2-positive precursor lymphoid cells in fetal liver). TAL-1 immunostaining is localized to the nucleus (Figure 6A-C) characteristically in the form of small dots whose number is greater than that of PML-positive structures. In mitotic cells, TAL-1 is consistently cytoplasmic.

**TAL-1 in hematologic neoplasia.** The TAL-1 gene is activated in about one fourth of all cases of T-ALL, but the link with expression of TAL-1 protein remains unclear. In several T-ALL lines, mRNA and/or protein was found in the absence of detectable gene rearrangement, and TAL-1 mRNA has been detected by reverse transcriptase–polymerase chain reaction (RT-PCR) in most cases of T-ALL. However, this may derive from normal monocytes and T cells in the samples: the results of an immunocytochemical study suggested that TAL-1 protein is only rarely expressed by leukemic cells in T-ALL when the gene is not rearranged.

**Clinical applications of TAL-1 immunostaining.** In a study by Chetty et al., samples from approximately 50% of T-ALL cases showed nuclear labeling, but the investigations were done in paraffin-embedded tissue, on which the available mAbs do not provide clean labeling. However, immunocytochemical labeling of fresh T-ALL samples that were also studied with molecular biologic techniques suggested that cases in which the TAL-1 gene is

![Figure 5. Expression of the PAX-5 (BSAP) transcription factor in neoplastic lymphoid cells.](image)

![Figure 6. TAL-1 expression in normal hemopoietic cells and neoplastic cell lines.](image)
rearranged can be detected by immunocytochemistry. There appears to be no correlation between TAL-1 gene rearrangement and clinical behavior in T-ALL.

### Fusion genes encoding chimeric proteins

Several chromosomal translocations cause fusion of unrelated genes rather than overexpression of intact quiescent genes, and these hybrid genes encode tumor-associated chimeric proteins.

This situation has reawakened interest in producing tumor-specific antibodies, but unfortunately, antibodies specific for the novel junctional regions in these chimeric proteins have proved to be difficult to raise. In addition, genes may break at different points and thus give rise to more than one fusion protein, with different junctional regions. In spite of these obstacles, progress has been made by using antibodies directed against nonjunctional parts of chimeric proteins, since such antibodies can detect relocalization (eg, PML) or de novo expression induced by gene fusion (eg, ALK).

#### The (15;17) translocation and its variants

**The PML and RARα genes.** The (15;17) chromosomal translocation, a specific marker for acute promyelocytic leukemia (APL), fuses the retinoic acid receptor-α (RARα) gene to a growth suppressor gene (PML) that encodes a protein thought to be involved in regulation of p53 acetylation and premature senescence induced by oncogenic Ras. The PML-RARα fusion protein may play a key role in the pathogenesis of APL by blocking terminal differentiation and inhibiting apoptotic cell death, and studies indicate that it acts by recruiting histone deacetylase through the RARα portion of the chimeric protein.

The rare cases of APL carrying variants of the t(15;17) (Table 1) have been identified resolved by gel electrophoresis. Antibodies to PML. Most PML isoforms and PML-RARα fusion proteins can be detected by immunocytochemical labeling with mAb PG-M3 (Table 3), which recognizes an epitope near the cysteine-rich (putative DNA-binding) region. Another anti-PML mAb (5E10) has been described, but it is directed against an epitope probably located in a region between amino acids 448 and 466 that is lost in some PML-RARα forms (eg, type S and bcr3 PML-RARα; Table 3). Anti-PML antibodies fail to identify endogenous PML in Western blotting analyses, possibly because of the small amounts of each PML isoform (13 have been identified) resolved by gel electrophoresis.

**PML in normal tissues.** Wild-type PML protein is expressed ubiquitously, but levels vary greatly according to cell type. PML protein is localized to discrete nuclear dots (average, 10 dots/nucleus) associated with nucleoli (Figure 7A). The diameter of these dots ranges from 0.5 to 1 μm and they correspond to nuclear domains (PML oncogenic domains [PODs]) reorganized previously by electron microscopy as “nuclear bodies” and by immunocytochemistry as “nuclear dots.” These macromolecular protein-rich complexes are tightly bound to the nuclear matrix and are known to contain several other proteins, including Sp100, NDP52, PIC1/SUMO-1, and Int-6. Progressive accretion of proteins gives rise to a characteristic ringlike appearance, especially in cells overexpressing PML.

**PML in hematologic neoplasia.** In leukemias other than APL (and in lymphomas), PML labeling consistently shows a wild-type speckled pattern (Figure 7A, right). In cells containing the PML-RARα fusion protein (eg, in APL blasts and transfected cells), the PML nuclear bodies are disrupted and the wild-type speckled pattern is replaced by a microspeckled pattern (Figure 7B) consisting of many tiny dots (often too numerous to count) in which PML-RARα and PML colocalize. Treatment of APL cells in vitro or in vivo with all-trans-retinoic-acid (ATRA) or arsenic trioxide (As2O3) restores the wild-type speckled PML pattern. Wild-type PML is often expressed at higher levels in Reed-Sternberg cells in HD than in neoplastic cells of other lymphoid malignant diseases.

**Clinical applications of PML immunostaining.** APL can be diagnosed rapidly by showing the microgranular PML immunocytochemical labeling pattern (Figure 7B). This appearance is
specific for APL with t(15;17), since the variants t(11;17) and t(5;17) do not disrupt the wild-type speckled pattern.\textsuperscript{181-184} Immunostaining must be done on fresh samples (smears, cytospin preparations, or frozen sections), since fixation and paraffin embedding change the wild-type speckled pattern to a diffuse pattern.\textsuperscript{160,177} Immunocytochemistry is especially useful in recognizing the microgranular variant of APL (M3V)—which is characterized by sparse cytoplasmic granules and marked nuclear irregularity, with folding, lobulation, or convolution—because it can be difficult to distinguish M3V from acute myelomonocytic or monoblastic leukemia (M4 and M5B).\textsuperscript{185} The immunocytochemical diagnosis of APL is clinically valuable because the disease responds to treatment with ATRA\textsuperscript{186,187} and As2O3.\textsuperscript{188} Variant translocations are not detected by immunostaining for PML, but they are rare and at least some of them, such as t(11;17), do not respond to ATRA treatment.\textsuperscript{149,189}

The (11;17) and (5;17) translocations. In the rare t(11;17) and t(5;17) anomalies, the portion of RAR\textalpha present in the PML–RAR\textalpha chimeric protein is fused to the Kruppel-like transcription factor PLZF or NuMA (the nuclear mitotic apparatus protein) (both of which are encoded by genes on chromosome 11), or to the amino-terminal of NPM.\textsuperscript{190,192} There are conflicting reports on the subcellular distribution of the PLZF protein: studies have observed localization to small punctate nuclear domains different from PODs,\textsuperscript{193} colocalization of PLZF and PML in nuclear bodies,\textsuperscript{194} and localization to 0.3- to 0.5-μm nuclear bodies (PLZF bodies) adjacent to but functionally distinct from PML nuclear bodies (Figure 7C).\textsuperscript{195} However, it is agreed that PLZF–RAR\textalpha and PML–RAR\textalpha colocalize in the same microspeckles,\textsuperscript{194,195} PLZF is expressed mainly in CD34\textsuperscript{+} progenitors\textsuperscript{196} but not in more mature myeloid cells, and it may also be involved in central nervous system differentiation.\textsuperscript{197} Because of the rarity of these APL molecular variants, no clinical studies of the value of antibodies to their products have been reported.

The NPM and ALK genes. The (2;5)(p23;q35) translocation, which is associated with ALCL,\textsuperscript{198-200} fuses the NPM gene, which encodes a receptor tyrosine kinase,\textsuperscript{201,202} to the amino-terminal portion of NPM linked to the entire intracytoplasmic domain of ALK.\textsuperscript{203-206} Six variant translocations in which ALK fuses to a partner other than NPM have been identified in human tumors\textsuperscript{207-213} (Table 4), but the classic NPM-ALK anomaly accounts for more than 80% of ALK fusion genes. The ALK gene appears not to be transcribed in normal lymphoid cells, but the promoter or promoters for NPM or other partners are assumed to induce transcription of the ALK fusion genes in lymphoma cells.\textsuperscript{201} NPM-ALK kinase activity is induced as a result of cross-linking by the NPM portion or one of the other fusion partners. Initial estimates of the frequency of t(2;5) and the resulting NPM-ALK gene in ALCL varied widely,\textsuperscript{214-219} but most of this uncertainty has since been resolved through immunocytochemical studies of ALK expression.

Antibodies to ALK. The laboratory that identified the p80 protein (later shown to be identical to NPM-ALK) prepared an affinity-purified polyclonal antibody to the kinase domain,\textsuperscript{220-222} and several immunocytochemical studies were conducted with samples made available to other researchers.\textsuperscript{218,219,223,224} A second polyclonal antibody (anti-ALK 11) has been used on a more limited scale for biochemical and immunocytochemical studies.\textsuperscript{225,226} However, most studies of ALK protein are now done with mAbs. Two such reagents have been described: ALK1 and ALKc. These recognize the cytoplasmic portion of ALK\textsuperscript{227,228} and are both suitable for immunolabeling paraffin-embedded biopsy specimens and for Western blot analyses.\textsuperscript{227,230}

Antibodies to NPM. MAbs against the carboxy-terminal portion of NPM were described more than 15 years ago.\textsuperscript{231} More recently, 3 paraffin-reactive antibodies recognizing epitopes on the carboxy-terminal portion (which is lost in the NPM-ALK hybrid kinase) or the amino-terminal portion (present in NPM-ALK) have been raised.\textsuperscript{232}

Expression of ALK and NPM in normal tissues and cell lines. ALK protein cannot be detected in tissues of human adults, except in a few cells in the nervous system that show weak labeling.\textsuperscript{227,228} RT-PCR has detected NPM-ALK and ATIC-ALK mRNA at low levels in normal and reactive lymphoid cells,\textsuperscript{233,234} but ALK-positive circulating cells cannot be detected by immunocytochemistry.\textsuperscript{227} Cell lines with t(2;5) are ALK positive, as are some neuroblastoma cell lines\textsuperscript{235} and the rhabdomyosarcoma line Rh30,\textsuperscript{227} all of which express full-length ALK protein.\textsuperscript{201,227} In contrast to ALK, NPM can be detected in most human cells by immunocytochemical techniques, usually confined to cell nuclei.\textsuperscript{232}

Expression of ALK in lymphoid neoplasia. The absence of ALK protein from normal lymphoid tissue means that positive ALK staining is a near-specific marker for lymphomas containing a hybrid ALK gene (Figure 8). When a lymphoma expresses ALK, the subcellular labeling pattern is informative (Table 4). Thus, in cases with the classic t(2;5), ALK is observed not only in the cytoplasm but also in the nucleus (Figure 8A), whereas tumors expressing ALK fusion proteins other than NPM-ALK show no nuclear labeling because they do not dimerize with wild-type NPM (Figure 8C).\textsuperscript{227,228,230,236,237} Furthermore, 2 ALK fusion proteins

---

**Table 4. Molecular abnormalities and subcellular distribution of fusion proteins in ALK-positive lymphomas**

<table>
<thead>
<tr>
<th>Fusion gene</th>
<th>Chromosomal abnormality</th>
<th>Molecular wt of fusion protein (kd)</th>
<th>Staining pattern of ALK protein</th>
<th>Staining pattern of NPM (N-terminal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPM-ALK</td>
<td>t(2;5)(p23;q35)</td>
<td>80</td>
<td>Nuclear and cytoplasmic</td>
<td>Nuclear and cytoplasmic</td>
</tr>
<tr>
<td>TPM3-ALK</td>
<td>t(1;2)(p21;p23)</td>
<td>104</td>
<td>Cytoplasmic</td>
<td>Nuclear</td>
</tr>
<tr>
<td>TPM4-ALK</td>
<td>t(2;19)(p23;p13.3)</td>
<td>100</td>
<td>Cytoplasmic</td>
<td>Nuclear</td>
</tr>
<tr>
<td>TFG-ALK</td>
<td>t(2;3)(p23;q21)</td>
<td>85 and 97</td>
<td>Cytoplasmic</td>
<td>Nuclear</td>
</tr>
<tr>
<td>ATIC-ALK</td>
<td>inv(2)(p23;q35)</td>
<td>95</td>
<td>Cytoplasmic (granular)</td>
<td>Nuclear</td>
</tr>
<tr>
<td>CLTCL-ALK</td>
<td>t(2;22)(p23;q11.2)</td>
<td>245</td>
<td>Membrane</td>
<td>Nuclear</td>
</tr>
<tr>
<td>MSN-ALK</td>
<td>t(X;2)(q11-12;p23)</td>
<td>125</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ALK indicates anaplastic lymphoma kinase; NPM, nucleophosmin; TPM3 and TPM4, nonmuscle tropomyosin 3 and 4; TFG, TRK-fused gene; ATIC, 5-aminimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; CLTCL, clathrin heavy chain-like gene; and MSN, moesin.

*Predicted on the basis of molecular studies but not observed cytoogenetically in ALK-positive lymphomas.
(CTCL-ALK and moesin-ALK) were found to have unique immunohistochemical staining patterns (granular cytoplasmic and membrane-associated, respectively; Figure 8C). Staining for the amino-terminal of NPM can also be informative because it is detected in both the cytoplasm and the nucleus in tumor cells with t(2;5), whereas staining in lymphomas with variant translocations is restricted to the nucleus. Western blotting of cryostat-section extracts can also be used to characterize variant ALK proteins, whose molecular weights differ from that of NPM-ALK.

Extensive immunohistologic studies have shown that ALK-positive tumors correspond only partly to what pathologists diagnosed in the past as ALCL. ALK-positive lymphomas typically contain a population of medium to large hallmark neoplastic cells, with a reniform eccentric nucleus and a juxtanuclear hof in the Golgi region. However, the morphologic variation is wide and includes cases with a relatively uniform proliferation of hallmark cells, tumors in which many bizarre large cells (sometimes with a sarcomatoid appearance) are observed, and neoplasms containing large numbers of macrophages (the lymphohistiocytic pattern) or other reactive cells.

ALK-positive lymphomas may contain areas of small cells that also express ALK protein. This indicates that the large cells do not represent cytolgic transformation of a small cell tumor after acquisition of an ALK translocation. In cutaneous T-cell lymphoma, cellular transformation can create this mixed large and small cell pattern, but these cases are ALK negative and lack the NPM-ALK gene. When the small cell component is prominent, the tumor is sometimes referred to as the “small cell variant” of ALK-positive lymphoma. There is no reason, however, to think of this as a different disease, although spread of the disease to the peripheral blood and bone marrow may be more likely in cases of this sort.

ALK-positive lymphomas usually express T-cell markers and/or cytotoxic granule proteins, CD30, and epithelial membrane antigen and c-Myc. Unlike ALK-negative cases, ALK-positive ALCLs are consistently BCL2 negative. We have found that tumors that are diagnosed morphologically as ALCL but have a B-cell phenotype are always ALK negative, and they probably represent one end of the morphologic spectrum of diffuse large B-cell neoplasia. Primary CD30-positive cutaneous lymphomas are also ALK negative, in keeping with the absence of the NPM-ALK gene. Finally, the controversial proposed “Hodgkin-like” subtype of ALCL is almost always ALK negative (as are Reed-Sternberg cells) and probably represents true HD.

Most important, lymphomas defined by ALK labeling appear to be clinically homogeneous, regardless of whether they have the classic t(2;5) or one of its variants. They are usually found in young men presenting with advanced disease (stage III-IV), are often associated with systemic symptoms (especially fever) and involvement of extranodal sites (especially skin, bone, and soft tissues), respond well to chemotherapy, and have a favorable outcome. Whether the high proliferative rate of the tumor, the host immune response to the ALK protein, or both these factors contribute to this pattern must be clarified in additional studies. In contrast, ALK-negative lymphomas with anaplastic large cell morphologic features tend to occur in older patients and usually have an unfavorable prognosis.

Rare cases of ALK-positive large B-cell lymphoma have been described. These are characterized by immunoblastic (rather than anaplastic) morphologic features, expression of full-length ALK, and cytoplasmic IgA (Figure 8C). The ALK-positive lymphomas with a B-cell phenotype described by Gascoyne et al may belong to this rare category, but there is insufficient information to confirm this.

ALK protein is not detectable in most nonhematopoietic neoplasms. The only exceptions are a few cases of rhabdomyosarcoma and neuroblastoma, both of which produce full-length ALK, possibly reflecting their primitive origin. In contrast, in the rare entity known as “inflammatory myofibroblastic tumor,” ALK expression is commonly found and appears to reflect the presence of an ALK fusion protein (eg, TPM3-ALK, TPM4-ALK, or clathrin-ALK).

**Clinical applications of anti-ALK antibodies.** Immunohistologic staining for ALK in lymphoid tissue biopsy specimens is now a widely used hematopathologic marker for diagnosing the clinicopathologic entity associated with t(2;5) and its variants, for which the name “ALK-positive lymphoma” seems most appropriate (rather than “ALCL”). ALK labeling can also be of value in discerning low levels of tumor tissue infiltration in such cases (eg, in bone marrow trephine specimens) and identifying cases in which the neoplastic cells are obscured by macrophages.
distinguished, because of its positive labeling for ALK, from peripheral T-cell lymphomas. Moreover, inflammatory myofibroblastic tumors\textsuperscript{228} that express the ALK protein as a result of translocations involving the ALK gene can also be distinguished by using ALK labeling, and the absence of CD30 distinguishes them from ALK-positive lymphomas.

Other translocations. Two translocations involving fusion of NPM with genes other than ALK have been described, and both are rare. The (5;17)(q32;q21) translocation in APL fuses the NPM gene to the RAR\textalpha{} gene,\textsuperscript{191} and the t(3;5)(q25.1;q34), which is found occasionally in myelodysplastic syndrome/acute myeloid leukemia,\textsuperscript{262} fuses NPM to the myelodysplasia/myeloid leukemia factor 1 (MLF1) gene. It was reported that the resulting NPM-MLF1 hybrid protein localizes to the nucleus, whereas wild-type MLF1 protein is found in the cytoplasm,\textsuperscript{262} thus indicating that the NPM moiety targets MLF1 to a novel site.

**Discussion**

Studies of the proteins encoded by genes involved in chromosomal alterations in hematologic neoplasia have lagged behind molecular biologic investigations of these anomalies because of the investment of resources required to make satisfactory antibodies, a process that depends on the availability of antigen. It is sometimes possible to raise highly specific antibodies against synthetic peptides (eg, anti-BCL-2\textsuperscript{27} and PML\textsuperscript{154}), but the best immunogens are probably recombinant proteins, the production of which is not simple. Furthermore, although polyclonal reagents have been used for immunocytochemical studies and Western blotting analyses (in which nonspecific reactions can be to some extent ignored), they may introduce problems of nonspecific reactivity, variation between different samples, and limited availability. Therefore, mAbs are preferable, but reagents that satisfy stringent criteria for specificity are not easy to produce. Antibodies should detect fixation-resistant epitopes in paraffin-embedded tissue, but those that meet this requirement are more difficult to produce.

Despite these problems, specific antibodies to the products of genes involved in hematologic neoplasia have provided major new insights, particularly when the protein target is relevant not only to hematologic neoplasia specifically but also to cell physiology in general. The best of example of this is BCL-2, a protein that was first studied in lymphomas with the t(14;18) but that subsequently was found to be extremely important in apoptosis.

Most antibodies discussed here can detect their targets through biochemical methods (Western blotting or immunoprecipitation). These techniques are particularly applicable to the study of hybrid genes, since they allow chimeric proteins (eg, the products of the hybrid BCR-ABL and NPM-ALK genes\textsuperscript{239,263,264}) to be distinguished from wild-type proteins on the basis of their unique molecular sizes. Biochemical analysis can also be useful when a gene (eg, AML1\textsuperscript{265}) encodes several transcripts. However, compared with immunocytochemistry, biochemical methods are more demanding technically and provide only limited information on tissue distribution and subcellular localization of the proteins.

Immunocytochemistry thus has obvious advantages for studying tissue distribution and localization. We have here discussed genetic anomalies that switch on quiescent genes separately from those that create fusion genes. For the anomalies that switch on genes, a major consideration is the expression pattern of the gene product in normal cells. Immunocytochemical studies of widely expressed genes (eg, c-MYC) generally have little clinical value. In the same way, for fusion genes, the particular distribution of the fusion protein can provide insights, particularly when the protein target is relevant not only to hematologic neoplasia specifically but also to cell physiology in general. The best example of this is BCL-2, a protein that was first studied in lymphomas with the t(14;18) but that subsequently was found to be extremely important in apoptosis.

Most antibodies discussed here can detect their targets through biochemical methods (Western blotting or immunoprecipitation). These techniques are particularly applicable to the study of hybrid genes, since they allow chimeric proteins (eg, the products of the hybrid BCR-ABL and NPM-ALK genes\textsuperscript{239,263,264}) to be distinguished from wild-type proteins on the basis of their unique molecular sizes. Biochemical analysis can also be useful when a gene (eg, AML1\textsuperscript{265}) encodes several transcripts. However, compared with immunocytochemistry, biochemical methods are more demanding technically and provide only limited information on tissue distribution and subcellular localization of the proteins.

**Table 5. Relocation of proteins in hematologic neoplasia after hybrid gene formation**

<table>
<thead>
<tr>
<th>Fusion protein</th>
<th>Location of wild-type proteins</th>
<th>New site of fusion protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>PML-RAR\textalpha{}\textsuperscript{186-189}</td>
<td>PML: in large nuclear bodies (PML oncogenic domains)</td>
<td>Multiple small intranuclear bodies</td>
</tr>
<tr>
<td>PLZF-RAR\textalpha{}\textsuperscript{181,185}</td>
<td>PLZF: in 0.3-0.5 (\mu)m nuclear bodies\textsuperscript{†}</td>
<td>Multiple small intranuclear bodies</td>
</tr>
<tr>
<td>NPM-RAR\textalpha{}\textsuperscript{182}</td>
<td>NPM: in nucleoli</td>
<td>Diffuse pattern throughout nucleus</td>
</tr>
<tr>
<td>NuMA-RAR\textalpha{}\textsuperscript{182}</td>
<td>NuMA: diffusely distributed in nucleus</td>
<td>Sheerlike aggregates of protein in nucleus</td>
</tr>
<tr>
<td>BCR-ABL\textsuperscript{227}</td>
<td>ABL: associated with cell-surface membrane and cytoplasm</td>
<td>Nucleus</td>
</tr>
<tr>
<td>E2A-PBX\textsuperscript{225}</td>
<td>E2A and PBX: in cytoplasm</td>
<td>Spherical intranuclear bodies</td>
</tr>
<tr>
<td>NPM-ALK\textsuperscript{277}</td>
<td>ALK: associated with cell-surface membrane and cytoplasm</td>
<td>Cytoplasm and nucleous (nucleoli)</td>
</tr>
<tr>
<td>CAN-DEK and CAN-SET\textsuperscript{299}</td>
<td>CAN: associated with nuclear envelope</td>
<td>Nuclear</td>
</tr>
</tbody>
</table>

\*None of these fusion proteins alter localization of the PML wild-type protein.\n\†Adjacent to but functionally distinct from PML nuclear bodies.\textsuperscript{195}\n\‡Colocalization with targeting sites of PML-RAR\textalpha{} is observed.

**Figure 9. Microarray patterns of mRNA expression for 7 lymphoid-associated genes in normal and neoplastic lymphoid cells.** These data are from a series reported by Alizadeh et al (http://llmpp.nih.gov/lymphoma) that included samples of diffuse large B-cell lymphomas. On the basis of microarray analysis, these tumors were assigned to 2 categories (with different clinical behavior), with one resembling germinal-center cells and the other having an activated B-cell phenotype. The frequency of positive immunostaining for the 7 markers in diffuse large B-cell lymphomas indicated by published studies and the authors’ experience is indicated beneath the microarray images. Act B indicates activated B cells; B, B cells; CLL, B-cell chronic lymphocytic lymphoma; Foll Ly, follicular lymphoma; GC, germinal-center cells; and T, T cells.
contrast, few normal cells express the products of the BCL-1 and TAL-1 genes, and immunocytochemical staining for these proteins has a role in the diagnosis of mantle cell lymphoma and T-ALL, respectively.

Molecules such as BCL-2 and BCL-6 are in an intermediate position: both are expressed by many cells in the absence of gene rearrangement, but immunocytochemical labeling can be useful in certain situations. For example, BCL-2 is a good marker for the t(14;18) if normal germinal-center B cells, which are consistently BCL-2 negative, are compared with their neoplastic counterparts, follicular lymphoma cells, which are usually BCL-2 positive. Thus, immunocytochemical detection of BCL-2 protein has a diagnostic role in distinguishing between reactive and neoplastic follicle centers, even though it is widely expressed outside the germinal center. BCL-6 is not a comparably specific immunocytochemical marker for gene translocation (even in a restricted context), but it has diagnostic value as a molecule associated with germinal-center cells.

Antibodies to chimeric proteins generated by fusion genes are theoretically less suitable for immunocytochemical analyses, since they are usually raised against one of the 2 constituent proteins and therefore react with both wild-type and hybrid proteins. Antibodies specific for junctional epitopes unique to the chimeric protein should avoid this problem, but despite reports of such epitopes on the BCR-ABL, 266,267 AML-ETO, 265 and E2A-PBX1 266 chimeric proteins—created respectively by t(9;22), t(8;21), and t(1;19)—the only antibodies that appear potentially suitable for immunocytochemical use are monoclonal reagents specific for the E2A-PBX1 junction. 266 This, however, appears to have not been used since their initial description.

Therefore, although in theory it should be possible to produce antibodies specific for hybrid proteins, in practice such antibodies remain elusive. If short recombinant protein sequences (or synthetic peptides) are used as immunogens, the junctional region may not adopt the same 3-dimensional conformation that it has in the chimeric protein in vivo. Furthermore, the junctional sequences may not be immunogenic, an issue that has been addressed, at least with respect to T-cell recognition, in several studies. For example, there is evidence that junctional BCR-ABL peptides can be bound by HLA class I molecules, 266,267 and several investigators 271 have reported that in vitro immunization with a peptide from p210 BCR-ABL can elicit a specific cytotoxic response. However, it is not yet clear whether the BCR-ABL junctional sequence is immunogenic in vivo. 266 Peptides eluted from HLA molecules on fresh chronic myeloid leukemia cells include those from the BCR protein but not junctional sequences. 272

Antibodies specific for chimeric oncogene products will therefore always be difficult, if not impossible, to produce. However, the 2 examples discussed here (PML-RARα and NPM-ALK) show that antibodies to normal constituents of a hybrid protein can be used to detect underlying genetic abnormalities. In the case of t(15;17), the intranuclear distribution of the chimeric PML-ALK is so distinctively different from that of wild-type PML that the existence of the NPM-ALK hybrid gene can reliably be inferred. The presence of the NPM-ALK fusion gene generated by t(2;5) can be assumed when a tumor shows ALK labeling in the nucleus and cytoplasm. When labeling is restricted to the cytoplasm, a variant hybrid ALK gene is likely to be present (since ALK protein is not expressed in normal lymphoid tissues), and labeling and Western blotting with anti-NPM can confirm this. ALK therefore behaves like proteins such as BCL-1 or BCL-2, which are switched on by gene rearrangement. Because of the absence of ALK protein from normal lymphohemopoietic cells, ALK fulfills most of the criteria for that elusive entity—a tumor-specific antigenic marker.

Immunocytochemical labeling for the NPM-ALK chimeric protein illustrates a point of wider relevance: the importance of subcellular localization patterns. Several proteins move from the cytoplasm to the nucleus under physiologic conditions. For example, the dimeric β50/β55 nuclear factor-κB transcription factor is normally held in the cytoplasm by the inhibitor protein IκB, but it translocates to the nucleus when IκB is inactivated by phosphorylation. 274 Epidermal growth factor was also found to relocate to the nucleus, after binding of its ligand. 273,274 Such observations are often made when proteins affected by genetic changes in hematologic neoplasia alter their subcellular localization (Table 5), and it is frequently concluded that the sites to which proteins relocate must be the sites of their oncogenic action. However, the NPM-ALK chimeric protein, for example, despite its prominent nuclear (and, in particular, nucleolar) localization, almost certainly exerts its lymphomagenic effect within the cytoplasm. 275 The chimeric PML-RARα protein shows no tendency to associate with nucleoli; thus, the hybrid NPM-RARα that is produced in rare cases of APL (and which presumably also accumulates in nucleoli) probably does not exert its transforming effect at this site.

Another leukemia-associated protein that relocates to a site that may not be relevant to its action is PML, which is displaced in APL cells from its normal target sites (ie, nuclear bodies) through heterodimerization with the PML-RARα fusion protein. 156,161,162,164 However, a PML-RARα mutant that cannot dimerize with PML in common precipitation experiments and does not delocalize PML from the nuclear bodies is nevertheless also capable of blocking differentiation. 276 Moreover, in some cases of APL, there are variant translocations that presumably contribute directly to leukemogenesis but that encode fusion proteins (PLZF-RARα, 190 NPM-RARα, 191 and NuMA-RARα 192) that do not alter the localization of PML, thereby suggesting that interference with retinoid signaling rather than disruption of PML nuclear bodies is the important event.

In conclusion, antibodies specific for the products of genes involved in chromosomal changes in leukemia and lymphoma have proved to be valuable both for studying normal cell physiology (eg, BCL-2) and for diagnosis (eg, BCL-1, PML, and NPM-ALK). The scope of antibody-based studies should continue to expand as new genetic changes in lymphoma and leukemia are identified. 279 Furthermore, microarray studies of the expression of large numbers of gene sequences are likely to reveal new potential immunocytochemical markers of clinical relevance associated with subtypes of disease 280-282 or prognosis. 280 However, researchers choosing candidate proteins against which to raise antibodies must recognize that the level of mRNA extracted from a cell suspension (and particularly from a biopsy specimen) does not necessarily correlate with the level of the corresponding protein in the tumor cells. This consideration is relevant to a microarray study of human B-cell lymphoma. 282 Figure 9 shows the mRNA expression data from this study for protein markers previously investigated immunohistologically in DLCL. The mRNA patterns for purified cells appear to correlate with protein expression (eg, the absence of B-cell gene expression in T cells and the expression of CD10 and BCL-2 in purified germinal-center cells). However, expression of the proteins studied is known to range in DLCL from less than 40% of cases (CD10) to essentially all cases (class II, CD20, and CD79), and these documented differences in protein expression are not, at least on first inspection, reflected in the mRNA profiles for the corresponding genes, which show little obvious differences.
Thus, the process of translating new molecular biologic findings into practical antibody-based techniques for assessing human tumor samples will continue to require a combination of judicious discrimination in choosing clinically important molecules and skill in making and characterizing specific antibodies. Given the large number of genes from which to choose the right candidates and the lottery-like nature of mAb production, an element of luck would also help!

Acknowledgments

This article is dedicated to the memory of Carlo Falini. The authors also wish to express their gratitude to their collaborators who have contributed with great skill over the years to the production and characterizing many of the reagents referred to in this review.

References

19. Chan JKC. Reliable immunostaining of cyclin D1 is difficult, but the problems can be overcome. Histopathology. 1999;34:266-268.


Ben-Ezra JM, King BE, Harris AC, Todd WM, Komornstein MJ. Staining for Bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies. Mod Pathol. 1994;7:560-564.


Ben-Ezra JM, King BE, Harris AC, Todd WM, Komornstein MJ. Staining for Bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies. Mod Pathol. 1994;7:560-564.


Be H, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre forma-


Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry

Brunangelo Falini and David Y. Mason